Dinaciclib is a novel potent small molecule inhibitor of cyclin-dependent kinases (CDK)1, CDK2, CDK5, and CDK9. Patients with relapsed multiple myeloma and 5 prior lines of therapy, with measurable disease, were enrolled.
For research use only. We do not sell to patients.
Name | Dinaciclib(SCH-727965) |
---|---|
Iupac Chemical Name | (S)-3-(((3-Ethyl-5-(2-(2-hydroxyethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl)amino)methyl)pyridine 1-oxide |
Synonyms | SCH727965 |
Molecular Formula | C21H28N6O2 |
Molecular Weight | 396.49 |
Smile | C(C)C=1C=NN2C1N=C(C=C2NCC=2C=[N+](C=CC2)[O-])N2[C@@H](CCCC2)CCO |
InChiKey | PIMQWRZWLQKKBJ-SFHVURJKSA-N |
InChi | InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1 |
CAS Number | 779353-01-4 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | crystalline solid |
---|---|
Purity | >98% by HPLC |
Storage | 3 years -20ºCpowder |
Solubility | Soluble in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |